Key Highlights

  • Lilly's Q1 2026 Revenue rose 56% to $19.8 billion, with Operating Income up 141% and full-year guidance raised to $82.0–$85.0 billion and $35.50–$37.00 in non-GAAP EPS.
  • The oral GLP-1 Foundayo is trailing Novo's oral Wegovy by roughly six to one on weekly US scripts, making the August 5 launch commentary more consequential than the headline revenue beat or miss.
  • At about 32 times forward Earnings and 1.2% free Cash Flow Yield , the stock prices in continued execution; realized prices already fell 13% year over year in Q1.
  • Lilly reports second-quarter 2026 results on August 5 and hosts a conference call at 10 a.m. Eastern.

The launch that changed the question

Lilly (NYSE:LLY) reports second-quarter 2026 results on August 5 and hosts a conference call at 10 a.m. Eastern. Investors already know roughly what the injectables will do. What they do not know is whether the company's oral GLP-1, Foundayo (orforglipron), is a slow starter or a genuine miss.

The FDA approved Foundayo for adults with obesity or overweight plus a weight-related condition, with shipping through LillyDirect beginning April 9. It is a once-daily small-molecule pill with no food or water timing restrictions, a real convenience advantage over the peptide alternative. The commercial reality so far has been less flattering. Fierce Pharma's oral GLP-1 launch tracker, published July 31, put Foundayo at roughly 29,400 weekly US prescriptions, against about 171,700 for Novo Nordisk's oral Wegovy, which launched in January and reached three million cumulative US scripts in five months. Lilly's pill relied heavily on direct-to-patient channels early on, about 45% of week-three Volume , while broad pharmacy benefit coverage arrived later, with CVS adding it on June 1.

The Franchise itself is not in question. Zepbound still accounts for roughly 58.9% of total US obesity prescriptions on the same tracker. The question is narrower and more expensive: whether Lilly's next act carries the same pricing power.

Two sessions undid a month of gains

Shares closed at $1,148.84 at last closing, down 0.53% on the day. That followed a 4.55% drop on July 30 on about 3.0 million shares, roughly 50% above the recent daily average. From the July 28 close of $1,220.66, the stock shed 5.9% in three sessions and finished the month about 8% below its 52-week high of $1,249.45. The 52-week low is $623.78, and the stock is still up roughly 51% over twelve months, with a market Capitalization near $1.02 trillion on 891.7 million shares outstanding.

The move fits a market repricing expectations rather than one reacting to a discrete disclosure. No adverse trial readout or regulatory action was announced in that window; what shifted was the read-through from competitor script data and the approach of an earnings print that will settle the argument.

What the last full set of books showed

First-quarter 2026 revenue reached $19.8 billion, up 56%, split $12.1 billion in the US (up 43%) and $7.7 billion outside it (up 81%). Volume grew 65% while realized prices fell 13%, the defining tension in this Business . Mounjaro contributed $8.7 billion, up 125%; Zepbound added $4.1 billion in the US, up 79%.

Profitability scaled faster than sales. Gross Margin ran at 81.9% of revenue, R&D at $3.5 billion (18% of revenue) and SG&A at $2.9 billion, producing operating income of $8.9 billion, up 141%. Reported EPS was $8.26 and non-GAAP EPS $8.55, up 170% and 156% respectively. Management raised full-year guidance to $82.0–$85.0 billion of revenue and $35.50–$37.00 in non-GAAP EPS, with a performance margin of 47.0%–48.5%.

Underneath the growth sits heavy reinvestment. Trailing Operating Cash Flow of $20.5 billion converted to $11.8 billion of free cash flow, reflecting a capital program tied to a pledge of more than $50 billion in US Manufacturing . Total Debt stands at $43.4 billion against $5.3 billion of cash. Consensus compiled by Hudson Labs ahead of the print looks for Q2 revenue of about $20.5 billion and EPS of $7.74, sequentially lower than Q1, consistent with the low-to-mid-teens price erosion management has guided to.

The pipeline behind the multiple

Retatrutide, a GIP/GLP-1/glucagon triple agonist, is the successor asset. In TRIUMPH-2, patients with type 2 diabetes and obesity lost up to 49.6 lbs (20.8%) at 80 weeks with A1C reductions of up to 1.6% at the 12 mg dose; TRIUMPH-3, in severe obesity with cardiovascular disease, showed up to 55.8 lbs (22.6%). Lilly said on July 23 that it plans to file a Biologics License Application in the first quarter of 2027, targeting obesity, knee osteoarthritis pain and obstructive sleep apnea.

Away from incretins, the newer launches are compounding off small bases, Jaypirca at $165 million in Q1, Ebglyss $145 million, Kisunla $124 million, Omvoh $80 million. Business development has been aggressive, headlined by the $6.3 billion Acquisition of Centessa Pharmaceuticals in March at $38 per share, with contingent value rights lifting the potential total to $47, for the orexin agonist cleminorexton in Phase 2a for narcolepsy and idiopathic hypersomnia.

The case for paying up

Volume growth of 65% against a 13% price decline says the constraint is Demand capture, not demand. Operating Leverage is real: operating income grew more than twice as fast as revenue. Lilly also has the durability piece competitors lack, with an approved pill, a Phase 3 triple agonist and a pricing accommodation with Washington, including Tariff relief and protection from future pricing mandates, already banked.

The case for caution

Foundayo's launch is the counterargument. If a convenience-advantaged pill cannot outsell a rival's oral peptide by a wide margin, the pricing premium embedded in Lilly's multiple is vulnerable. Government pricing commitments, $50 a month for Medicare beneficiaries, self-pay from $149, institutionalize the Deflation already visible in reported prices. Free cash flow conversion is modest relative to earnings while the capex cycle runs, and net debt near $37.6 billion is no longer trivial.

Valuation leaves no room for a stumble

Trailing revenue of $72.3 billion (up 47.4%) and trailing EPS of $28.15 put the stock on about 41 times trailing earnings and roughly 32 times forward. On the midpoint of management's own FY26 non-GAAP guidance, $36.25, the multiple is about 31.7 times. Price-to-sales is 14.2 trailing and 11.7 forward, EV/revenue 14.7 and EV/EBITDA 31.6, with a PEG of 1.42. Free cash flow yield is roughly 1.2%.

The contrast with Novo Nordisk is stark. At $51.03 on July 30, Novo carried a $227.6 billion market capitalization, a trailing P/E of 12.1 and a forward P/E of 16.9 on trailing revenue growth of 8.1%. The market is paying nearly triple the forward multiple for roughly six times the growth rate, a defensible trade only while the growth holds.

Upcoming Catalysts

  • Q2 2026 results. Foundayo prescription volumes, channel mix, gross margin trend and whether FY26 guidance moves again.
  • Foundayo coverage expansion, through H2 2026. Broader PBM formulary wins would show whether the slow start was access-driven rather than demand-driven.
  • Retatrutide BLA submission, Q1 2027. Filing on schedule keeps the obesity franchise's second act on track for a late-decade launch.
  • Medicare $50-a-month pricing implementation, 2026. Lilly's disclosures give conflicting start dates; the realized mix effect should appear in second-half results.

Principal Risks

  • Oral GLP-1 share loss. Novo's three-month head start and full PBM coverage at launch have given oral Wegovy a lead that Foundayo has yet to close, threatening the assumption that Lilly dominates the next segment.
  • Structural price erosion. Realized prices fell 13% in Q1, and government pricing commitments lock in low out-of-pocket levels across Medicare and self-pay channels.
  • Valuation compression. A forward multiple near 32 times leaves little cushion; the 5.9% three-session decline into month-end showed how quickly sentiment can reset.
  • Capital intensity and leverage. More than $50 billion of committed US manufacturing spend and $43.4 billion of gross debt constrain free cash flow while the build-out continues.
  • Pipeline concentration. Retatrutide and the incretin franchise carry a disproportionate share of the growth narrative; a safety or regulatory setback would be difficult to offset with the smaller launches.

Conclusion

Lilly's Q1 2026 revenue rose 56% to $19.8 billion, with operating income up 141% and full-year guidance raised to $82.0–$85.0 billion and $35.50–$37.00 in non-GAAP EPS. Set against that: Novo's three-month head start and full PBM coverage at launch have given oral Wegovy a lead that Foundayo has yet to close, threatening the assumption that Lilly dominates the next segment. That tension shows up in the valuation: At about 32 times forward earnings and 1.2% free cash flow yield, the stock prices in continued execution; realized prices already fell 13% year over year in Q1. The next real test: Foundayo prescription volumes, channel mix, gross margin trend and whether FY26 guidance moves again.

This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.